The Confounding Case of Venetoclax in Multiple Myeloma
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo.
Multiple Myeloma
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
BCMA CAR-T bb2121 Appears to Be Safe and Effective in Multiple Myeloma
An anti-BCMA CAR-T therapy appeared to be safe and effective for patients with relapsed or refractory multiple myeloma.
Study Reports Marijuana Use Among Patients With Cancer May Be Increasing While Opioid Use Stays Stable, but Questions Remain
The proportion of participants with cancer who used marijuana increased 118% from the period of 2005 to 2014.
Intensive Chemotherapy May Be Beneficial for Younger Patients With Myelodysplastic Syndrome
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.
CD33 and MPC-1: Monitoring Response to Bortezomib in Multiple Myeloma
CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy.
Patient Pain, QoL Associated With Salvage ASCT in Myeloma Must Be Balanced With Survival Benefit
A new study gives a comprehensive picture of patient quality of life before and after salvage transplant.
CAR-T in Multiple Myeloma: Promising Efficacy and Generally Manageable Toxicity
Interestingly, a number of patients ultimately achieving a sustained complete response initially experienced a partial response to this CAR T-cell therapy.
Next post in Multiple Myeloma
